Genprex, Inc. Files 8-K
Ticker: GNPX · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1595248
Sentiment: neutral
Topics: sec-filing, 8-k, pharmaceuticals
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on 10/28/25, check it for updates.
AI Summary
Genprex, Inc. filed an 8-K on October 28, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Austin, Texas, operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates Genprex, Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) that typically reports significant events or financial updates, not inherently indicating high risk.
Key Numbers
- 001-38244 — Commission File Number (Identifies the company's SEC filing history)
- 90-0772347 — I.R.S. Employer Identification Number (Tax identification number for the company)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- October 28, 2025 (date) — Date of report
- Austin, TX (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific 'Other Events' are being reported by Genprex, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the provided text excerpt.
What is the SIC code for Genprex, Inc. and what does it signify?
The SIC code is 2834, which corresponds to 'Pharmaceutical Preparations', indicating the company's industry.
When is Genprex, Inc.'s fiscal year end?
Genprex, Inc.'s fiscal year ends on December 31 (1231).
What is the primary business address of Genprex, Inc.?
The primary business address is 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the telephone number for Genprex, Inc.?
The telephone number for Genprex, Inc. is (512) 537-7997.
Filing Stats: 1,169 words · 5 min read · ~4 pages · Grade level 16 · Accepted 2025-10-28 08:19:08
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251024c_8k.htm (8-K) — 32KB
- 0001437749-25-031856.txt ( ) — 165KB
- gnpx-20251028.xsd (EX-101.SCH) — 3KB
- gnpx-20251028_def.xml (EX-101.DEF) — 12KB
- gnpx-20251028_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251028_pre.xml (EX-101.PRE) — 12KB
- gnpx20251024c_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 28, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing that its research collaborators presented positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics which took place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators presented positive preclinical data from a study of Genprex's lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), for the treatment of ALK-EML4 positive ("ALK+") non-small cell lung cancer ("NSCLC"). The poster session described that in the study, researchers demonstrated that REQORSA can overexpress the tumor suppressor gene, TUSC2, in EML4-ALK+ NSCLC cell lines and patient derived organoids. The upregulation of TUSC2 by REQORSA therapy induced apoptosis in ALK+ NSCLC cells, including those resistant to alectinib. Researchers also demonstrated in the study that combining REQORSA with alectinib further increases apoptosis. Using in vivo mouse experiments with xenografts of a human ALK+-EML4 NSCLC cell line, treatment with REQORSA and alectinib together improved survival when compared to control. These experiments provide support for a trial of REQORSA in patients with ALK+-EML4 NSCLC. The press release noted that the data also add to the existing preclinical data showing that REQORSA has significant activity on its own as well as when combined with other therapies in a mouse xenograft model with ALK-EML4 rearrangement. The combination of REQORSA and an ALK inhibitor led to longer survival in the mouse model in the study. The Company believes these positive data open a pathway for a potential future clinical trial in ALK-positive lung cancer. Cautionary Language Concerning Forward-Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: October 28, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)